Matthew Cary
Family · Saint Louis, MONPI 1619233525
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Gilead at 45.9% of the total. Reporting peaked in 2024 at $7,865 and has fallen 54.9% since, to $3,549 in 2025. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 523 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Viiv Healthcare Company$3K
- Theratechnologies Inc.$713
- Lilly USA, LLC$589
- Merck$567
- Johnson & Johnson$567
- plus $2K from 23 others
What the payments were for
- Consulting fees$3,68024%
- Speaking & faculty fees$350%
- Travel & lodging$2,29715%
- Food & beverage$8,74758%
- Education$3252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 108 | $6,928 |
| Viiv Healthcare Company | 157 | $3,476 |
| Theratechnologies Inc. | 21 | $713 |
| Lilly USA, LLC | 31 | $589 |
| Merck | 22 | $567 |
| Johnson & Johnson | 65 | $567 |
| Napo Pharmaceuticals Inc | 15 | $377 |
| Novo Nordisk | 20 | $301 |
| Amgen | 14 | $247 |
| EMD Serono, Inc. | 11 | $215 |
| AstraZeneca | 11 | $201 |
| Otsuka America Pharmaceutical, Inc. | 9 | $195 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Halozyme Inc | 4 | $64 |
| AbbVie | 2 | $51 |
| Antares Pharma, Inc. | 3 | $49 |
| Hologic Sales And Service, LLC | 2 | $48 |
| Janssen Scientific Affairs, LLC | 2 | $44 |
| Acerus Pharmaceuticals Corporation | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| VBI Vaccine (delaware) Inc. | 2 | $39 |
| Exact Sciences | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Pfizer | 2 | $30 |
| Mirum Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Insmed, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,085 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $187,233 |
| Egrifta SvTesamorelin Acetate | 22 | $159,342 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 15 | $110,222 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 27 | $101,177 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 24 | $95,949 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $94,418 |
| DovatoDolutegravir Sodium/Lamivudine | 26 | $86,752 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $51,977 |
| TivicayDolutegravir Sodium | 15 | $48,884 |
| OzempicSemaglutide | 19 | $29,299 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $24,799 |
| PifeltroDoravirine | 13 | $22,778 |
| MounjaroTirzepatide | 16 | $17,006 |
| EliquisApixaban | 20 | $14,025 |
| Repatha SureclickEvolocumab | 20 | $10,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $6,928 | $307,98181 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Triumeq, Tivicay | $3,476 | $282,03169 claims |
| Theratechnologies Inc.Egrifta Sv | $713 | $159,34222 claims |
| Novo NordiskOzempic | $301 | $29,29919 claims |
| Lilly USA, LLCMounjaro, Trulicity | $589 | $27,82027 claims |
| MerckPifeltro | $567 | $22,77813 claims |
| PfizerEliquis | $30 | $14,02520 claims |
| Johnson & JohnsonXarelto | $567 | $7,45013 claims |
| AbbVieLinzess | $51 | $6,06112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Saint Louis
- Rebecca SeabaughSaint Louis$68K
- Jordan PerezSaint Louis$43K
- Lindsay GwaltneySaint Louis$28K
- Sara WoottenSaint Louis$21K
- Kelly RobertsSaint Louis$17K
- Philip DudakSaint Louis$14K
- Kenan SahbazSaint Louis$14K
- Nicole CarrSaint Louis$14K
- Ashley GarrettSaint Louis$12K
- Monica SanchezSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.